1. Scrip

FDA advisers back Rockwell's Triferic to treat iron loss

 
• By Donna Young

The FDA's Oncologic Drugs Advisory Committee (ODAC) on 6 November voted 8-3 to back approval of Rockwell Medical's Triferic (ferric pyrophosphate) as a treatment for iron loss, declaring the company's efficacy and safety results supported the product's benefit over its risk.

The FDA's Oncologic Drugs Advisory Committee (ODAC) on 6 November voted 8-3 to back approval of Rockwell Medical's Triferic (ferric pyrophosphate) as a treatment for iron loss, declaring the company's efficacy and safety results supported the product's benefit over its risk.

Shares of Rockwell shot up 37.2%, or a gain of $3.47, in after-hours trading on 6 November.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas